Symptomtext
they administered the liquid part of PENTACEL (DTAP-IPV component) that was diluted with 0.5 ml sterile water but the lyophilized part (ACTHIB) was never given with no reported adverse event; they administered the liquid part of PENTACEL (DTAP-IPV component) that was diluted with 0.5 ml sterile water but the lyophilized part (ACTHIB) was never given with no reported adverse event; Initial information received on 01-Sep-2022 regarding an unsolicited valid non-serious case received from a consumer/non-health care professional. This case involves an unknown age and gender patient who was administered the liquid part of pentacel (dtap-ipv component) that was diluted with 0.5 ml sterile water but the lyophilized part (acthib) was never given with no reported adverse event , after receiving vaccines HIB (PRP/T) VACCINE [ACT-HIB] and DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received once a dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE (U7311AA and expiration date: 09-Sep-2023) and a dose of suspect HIB (PRP/T) VACCINE ( lot UJ757AA and expiration date: 09-Sep-2023) at an unknown dose via unknown route at unknown administration site for immunization. On 01-Sep-2022 t(latency: same day), the patient developed a non-serious event" they administered the liquid part of pentacel (dtap-ipv component) that was diluted with 0.5 ml sterile water but the lyophilized part (acthib) was never given with no reported adverse event" (single component of a two-component product administered) (product preparation error) following the administration. Action taken :not applicable. It was not reported if the patient received a corrective treatment for the events. Outcome: unknown for both events This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.